Sp256tumor Lysis Syndrome in Solid Tumors: Clinical Characteristics and Prognosis

Caravaca-Fontán, Fernando; Pampa-Saico, Saúl; Delgado-Yagüe, María; Yerovi, Estefanía; Olmedo, María Eugenia; Martínez-Sáez, Olga; Liaño, Fernando

doi:10.1093/ndt/gfx144.sp256

Cited by 9 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study conducted by Caravaca-Fontán et al, spontaneous TLS was detected in 47% of the patients. Spontaneous TLS in three of 8 patients with lung cancer, spontaneous TLS in one of two patients with oesophageal cancer, spontaneous TLS in a patient with colon cancer, spontaneous TLS in a patient with stomach cancer, spontaneous TLS in one of two patients with endometrium cancer, , spontaneous TLS in a patient with breast cancer, spontaneous TLS in a patient with prostate cancer, spontaneous TLS in a patient with germinal tumor, spontaneous TLS in a patient with germinal tumor, spontaneous TLS in a patient with liposarcoma and spontaneous TLS in a tumor of unknown origin were found 14 . In our study, TLS was detected after 46.8% 'indole chemotherapy, 37.5%' spontaneously, 9.3% after biopsy.…”

Section: Resultsmentioning

confidence: 96%

Assessment of tumor lysis syndrome cases

Hüzmelí¹

2019

Cumhuriyet Medical Journal

View full text Add to dashboard Cite

Tumor lysis syndrome (TLS) is a clinical picture that occurs with the rapid destruction of tumor cells and with life-threatening metabolic disorders. The aim of our study is to evaluate the etiologic causes, diagnosis and treatment of TLS cases. Method: The study was conducted between January 2015 and December 2017 in Kahramanmaras Necip Fazıl city Hospital. A total of 32 patients diagnosed with TLS were included in the study. Laboratory values of patients were scanned (blood urea nitrogen, creatinine, potassium, phosphorus, calcium, serum uric acid, lactate dehydrogenase) and diagnoses, chemotherapy and treatments were noted. Results: Of the 32 patients who were included in the study, 17 were male and 15 were female. The average age of the patients was found as 62,06 ± 12,10 (35-86) years. Hematologic malignancy was detected in the etiology of 11 of the TLS cases and solid tumor was detected in 21 of the TLS cases. A total of 12 (37.5%) patients had spontaneous TLS (5 in haematological malignancy and 7 in solid tumor). Hyperpotassaemia 50%, hypocalcaemia 46.9%, hyperphosphatemia, hyperuricemia and acute kidney damage was present in all patients. Mortality rate was found as 40.6%. Conclusions: In our study, spontaneous TLS was detected at a high rate. In addition, the mortality rate was also high. Early diagnosis and urgent treatment should be planned to avoid mortalities.

show abstract

Section: Resultsmentioning

confidence: 96%

Assessment of tumor lysis syndrome cases

Hüzmelí¹

2019

Cumhuriyet Medical Journal

View full text Add to dashboard Cite

show abstract

“…The estimated mortality rate for TLS in the setting of solid tumours ranges between 33% and 47% 1 19. With TLS in GIST, death occurred in three of the five reported cases.…”

Section: Discussionmentioning

confidence: 99%

“…The majority of cases of TLS are associated with treatment of rapidly proliferating tumours, particularly high-grade lymphomas and acute lymphoblastic leukaemia. Significantly fewer cases of TLS have been reported in association with solid tumours, either spontaneously or following treatment 1. A systematic review of reported TLS cases between 1977 and 2015 found only 120 reports of TLS occurring in patients with solid tumours 2.…”

Section: Introductionmentioning

confidence: 99%

Tumour lysis syndrome: a rare side effect of imatinib therapy for GIST

2018

View full text Add to dashboard Cite

Tumour lysis syndrome (TLS) is a life-threatening complication wherein massive tumour cell lysis results in severe metabolic abnormalities. TLS generally follows chemotherapy of rapidly proliferating haematological malignancies; spontaneous TLS and TLS from treatment of solid tumours are infrequently reported. We present a rare case of TLS following treatment of a large gastrointestinal stromal tumour (GIST) in a 63- year-old man. Imatinib was started for tumour size reduction prior to surgical intervention and in 5 days the patient developed metabolic derangements consistent with TLS. Imatinib was held and fluids, allopurinol and rasburicase were started. All metabolic abnormalities resolved in 3 days. Imatinib was restarted, and he eventually underwent surgical intervention. This is the second case demonstrating successful reinitiation of imatinib following TLS when treating GIST. We highlight the importance of risk factor assessment and need for pre-emptive therapy to prevent TLS when using tyrosine kinase inhibitor therapy.

show abstract

“…Specific characteristics of TLS were that it was frequently spontaneous and that, in the vast majority, patients were referred to palliative care upon the diagnosis of TLS, which is not the case in patients with high-grade malignant hemopathies (HM) [4]. The availability of targeted therapies has certainly changed the risk of TLS in this setting, although in an expected magnitude, that cannot explain the authors' findings [5]. A misclassification bias may explain this finding and may be explained by two nonexclusive factors.…”

mentioning

confidence: 96%